• About
  • Contact
  • Support Funtrafoo
  • Work With Us
No Result
View All Result
  • Home
  • FOOD
  • TRAVEL
  • HEALTH
  • TECHNOLOGY
  • LIFESTYLE
  • ENTERTAINMENT
  • EVENTS
  • FEEDS
  • WEB STORIES
  • Home
  • FOOD
  • TRAVEL
  • HEALTH
  • TECHNOLOGY
  • LIFESTYLE
  • ENTERTAINMENT
  • EVENTS
  • FEEDS
  • WEB STORIES
No Result
View All Result
No Result
View All Result
Home Daily Feeds

Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome

by PR Newswire
June 22, 2022
Reading Time: 11 mins read
0 0
0
ADVERTISEMENT
Share on FacebookShare on Twitter

Also Read

ZS Cares build city’s first ever STEM Robotics AI lab for Pune Zilla Parishad school students

“HRD status has emerged as an important biomarker in tumors that harbor high levels of DNA damage, such as ovarian, breast, prostate, and pancreatic cancers,” said Phil Febbo, MD, chief medical officer at Illumina. “With one sample and one test, TruSight Oncology 500 HRD assay provides labs with comprehensive, accurate, sensitive results that can greatly enhance our understanding of the genomic nature of a tumor.”

The Research Use Only TruSight Oncology 500 HRD test is a next-generation sequencing (NGS)–based assay that harnesses the power of Illumina NGS technology and validated HRD technology from Myriad Genetics (NASDAQ: MYGN), enabling labs to accurately detect genomic instability and analyze more than 500 genes simultaneously, including those relevant to HRD status. HRD is a genomic signature used to describe when cells are unable to effectively repair double-stranded DNA breaks. When this occurs, cells rely on alternative, error-prone DNA repair mechanisms, which may lead to genomic instability and, eventually, tumor formation.

The Molecular Pathology Diagnostic Unit at the Technical University of Munich participated in the TSO 500 HRD early access program in order to compare the results of Illumina’s prototype TSO 500 HRD assay to a validated reference standard, from Myriad Genetics.

“Our institution is delighted by the release of TruSight Oncology 500 HRD and we are very happy with our results from the early access program,” said Nicole Pfarr, head of the Molecular Pathology Diagnostic Unit, Technische Universität München. “We look forward to using this assay routinely in our lab for future projects. Combining HRD assessment with TruSight Oncology 500 in one workflow will unlock the most comprehensive view of the tumor genome, while maintaining efficiency in the lab.”

Large-cohort studies show that comprehensive genomic profiling (CGP) has the potential to identify relevant genetic alterations in up to 90% of samples. A single, comprehensive assay to assess a wide range of biomarkers uses less sample and returns results more quickly compared to multiple, iterative tests. As a kitted, distributable solution, this test helps to remove barriers for internalization of CGP and HRD testing, so that labs of all sizes can offer this powerful test.

“We are pleased to reach this first milestone with Illumina to commercialize an assay for HRD assessment that will aid in advancing clinical research and broaden access to clinical trials,” said Dr. Eric H. Rubin, senior vice president, early-stage development, clinical oncology, Merck Research Laboratories.

The research test is expected to begin shipping globally (excluding the US and Japan) in August. In addition, as part of the partnership announced in September 2021, work is ongoing to develop a new HRD companion diagnostic (CDx) test for the EU and the UK to aid in the identification of ovarian cancer patients with positive HRD status.

This partnership expands on Illumina’s broad portfolio of oncology partnerships with industry leaders, with the united goal of advancing cancer diagnostics and precision medicine. 

About TruSight Oncology 500

TSO 500 is a Research Use Only pan-cancer assay that enables Comprehensive Genomic Profiling. Designed to identify known and emerging tumor biomarkers across 523 genes, TSO 500 utilizes both DNA and RNA from tumor samples to identify key variants critical for cancer development and progression, such as small DNA variants, fusions, and splice variants. In addition, the assay assesses key immune-oncology biomarkers, such as Tumor Mutational Burden (TMB), Microsatellite Instability (MSI) and Homologous Recombination Deficiency (HRD). Due to its comprehensive biomarker content, labs can consolidate multiple single-gene or small-panel workflows into a single assay, saving biopsy specimen and time. Click here to learn more.

Use of forward-looking statements

This release contains forward-looking statements that involve risks and uncertainties, including the expectation for lower costs related to the storing and managing of genomic data costs. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services; (ii) our ability to deploy new products, services, and applications, and to expand the markets for our technology platforms; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations once deployed, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

Investors:

Salli Schwartz

858.291.6421

IR@illumina.com

Media:

Adi Raval

US: 202.629.8172

PR@illumina.com

Photo – https://mma.prnewswire.com/media/1843487/Illumina_research_test_codeveloped_with_Merck.jpg

(This story is auto-generated from PR Newswire)

Tags: PR NewswirePress Releases
ShareTweetSendShare

Related Posts

ZS Cares build city’s first ever STEM Robotics AI lab for Pune Zilla Parishad school students

ZS Cares build city’s first ever STEM Robotics AI lab for Pune Zilla Parishad school students

July 6, 2022
1
Tredence Inc. Recognized as 2022 Microsoft Analytics Partner of the Year

Tredence Inc. Recognized as 2022 Microsoft Analytics Partner of the Year

July 6, 2022
0
NSDC, Auxilo Finserve collaborate to support funding for skilling & vocational courses; Aim to create portfolio of INR 1,000 crore over next 3 years

NSDC, Auxilo Finserve collaborate to support funding for skilling & vocational courses; Aim to create portfolio of INR 1,000 crore over next 3 years

July 6, 2022
0
TCG Lifesciences inaugurates a new R&D facility in Pune, as part of a major expansion

TCG Lifesciences inaugurates a new R&D facility in Pune, as part of a major expansion

July 5, 2022
1
No Result
View All Result
  • Coronavirus Vaccine Prices In India and Other Countries

    Coronavirus Vaccine Prices In India and Other Countries. Is Covid Vaccine Free?

    21 shares
    Share 21 Tweet 0
  • Padma Vibhushan, Padma Bhushan, Padma Shri: Full List Of Padma Award Winners 2021

    15 shares
    Share 15 Tweet 0
  • Importance And Benefits Of Vitamin D Rich Food

    1 shares
    Share 1 Tweet 0
  • Yoga Beginner’s Guide – Tips Before Attending The First Yoga Class

    1 shares
    Share 1 Tweet 0
  • Parliament of India: नया देश नया भवन

    0 shares
    Share 0 Tweet 0

Recent Posts

  • Steps To Download Covid-19 Vaccine Certificate Using Whatsapp
  • Celebrate International Cat Day (World Cat Day) On 8 August
  • Meet Neeraj Chopra Who Won 1st Gold Medal For India In Tokyo Olympics 2021
  • Robin Hood Army New Initiative #Mission28States To Help Vaccinate Underprivileged, Serve 5 Mn Meals
  • Top 10 most livable cities in the world
  • Home
  • Contact Us
  • About Us
  • Support Funtrafoo
  • Authors
FUN * TRAVEL * FOOD

© 2021 www.funtrafoo.com.

No Result
View All Result
  • Home
  • FOOD
  • TRAVEL
  • HEALTH
  • TECHNOLOGY
  • LIFESTYLE
  • ENTERTAINMENT
  • EVENTS
  • FEEDS
  • WEB STORIES

© 2021 www.funtrafoo.com.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In